From: Cellular immunotherapy for refractory hematological malignancies
 | AML/ALL | Lymphoma |
---|---|---|
Complete Remission (CR) | • No leukemic blasts in PB | Nodal |
• No extramedullary leukemia | • If PET positive prior to treatment then any mass provided PET negative. If PET negative or variably positive then nodal regression to normal size on CT | |
• BM cellularity > 20% without Auer rods and <5% blasts | ||
• ANC > 1.0 × 109/L | Spleen/Liver | |
• Platelet count > 100x109/L. | • Not palpable, resolution of nodules | |
Bone Marrow | ||
• Morphological clearance or if morphology equivocal then IHC normalization | ||
Partial Remission (PR) | • All criteria for CR except bone marrow may have 5-20% blasts | Nodal |
• ≥ 50% decrease in the SPD of up to 6 | ||
• largest masses | ||
Spleen/Liver | ||
• ≥ 50% decrease in SPD of nodules if multiple nodules, ≥ 50% in size of the transverse diameter of a single nodule if solitary mass | ||
Bone Marrow | ||
• No new bone marrow involvement | ||
Transient Response (TR) | • Loss of PB blasts | N/A |
• >50% reduction in BM blasts | ||
Stable Disease (SD) | N/A | • If PET positive pretreatment, then PET positive post treatment at previous sites. If PET negative pretreatment then no CT change in size of previous lesions. |